Literature DB >> 11602579

Molecular events in transmembrane signaling via E-selectin. SHP2 association, adaptor protein complex formation and ERK1/2 activation.

Y Hu1, B Szente, J M Kiely, M A Gimbrone.   

Abstract

E-selectin is a cytokine-inducible adhesion molecule that is expressed by activated endothelial cells at sites of inflammation. In addition to supporting rolling and stable arrest of leukocytes, there is increasing evidence that E-selectin functions in transmembrane signaling into endothelial cells during these adhesive interactions. We have previously shown that adhesion of HL-60 cells (which express ligands for E-selectin), or antibody-mediated cross-linking of E-selectin, results in formation of a Ras/Raf-1/phospho-MEK macrocomplex, extracellular signal-regulated protein kinase (ERK1/2) activation, and c-fos up-regulation. All of these downstream signaling events appear to require an intact cytoplasmic domain of E-selectin. Here we demonstrate that tyrosine 603 in the cytoplasmic domain of E-selectin is required for the E-selectin-dependent ERK1/2 activation. Tyrosine 603 plays an important role in mediating the association of E-selectin with SHP2, and the catalytic domain of SHP2 is, in turn, critical for E-selectin-dependent ERK1/2 activation. An adapter protein complex consisting of Shc.Grb2.Sos bridges between SHP2 and the Ras.Raf.phospho-MEK macrocomplex. These molecular events thus outline a mechanism by which cross-linking of E-selectin by engagement of ligands on adherent leukocytes can initiate a multifunctional signaling pathway in the activated endothelial cell at sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602579     DOI: 10.1074/jbc.M105513200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Clustering endothelial E-selectin in clathrin-coated pits and lipid rafts enhances leukocyte adhesion under flow.

Authors:  Hendra Setiadi; Rodger P McEver
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

2.  Defining SH2 domain and PTP specificity by screening combinatorial peptide libraries.

Authors:  Anne-Sophie Wavreille; Mathieu Garaud; Yanyan Zhang; Dehua Pei
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

3.  Melanoma upregulates ICAM-1 expression on endothelial cells through engagement of tumor CD44 with endothelial E-selectin and activation of a PKCα-p38-SP-1 pathway.

Authors:  Pu Zhang; Chris Goodrich; Changliang Fu; Cheng Dong
Journal:  FASEB J       Date:  2014-08-19       Impact factor: 5.191

4.  In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium.

Authors:  Maaike Everts; Gerben A Koning; Robbert J Kok; Sigridur A Asgeirsdóttir; Dietmar Vestweber; Dirk K F Meijer; Gert Storm; Grietje Molema
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

Review 5.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

6.  Eosinophil adhesion under flow conditions activates mechanosensitive signaling pathways in human endothelial cells.

Authors:  Susan L Cuvelier; Smitha Paul; Neda Shariat; Pina Colarusso; Kamala D Patel
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

7.  Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation.

Authors:  M Roh-Johnson; J J Bravo-Cordero; A Patsialou; V P Sharma; P Guo; H Liu; L Hodgson; J Condeelis
Journal:  Oncogene       Date:  2013-09-23       Impact factor: 9.867

Review 8.  Rho-GTPase signaling in leukocyte extravasation: an endothelial point of view.

Authors:  Niels Heemskerk; Jos van Rijssel; Jaap D van Buul
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

Review 9.  N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Authors:  Krzysztof Marek Mrozik; Orest William Blaschuk; Chee Man Cheong; Andrew Christopher William Zannettino; Kate Vandyke
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.